{"entity":{"id":"paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019","kind":"paper","name":"KEYNOTE-170: pembrolizumab in relapsed or refractory primary mediastinal large B-cell lymphoma","aka":[],"tldr":"Pembrolizumab produced responses in about 45 percent of patients with primary mediastinal B-cell lymphoma that had relapsed after chemotherapy, a lymphoma whose frequent 9p24.1 amplification makes it unusually sensitive to PD-1 blockade.","summary":"Phase 2 study of 53 patients with relapsed or refractory primary mediastinal large B-cell lymphoma treated with pembrolizumab, supported by a phase 1b cohort of 21 patients.\n\nObjective response was 45 percent with complete responses in 13 percent, median duration of response not reached after a median follow-up of 12.5 months, and no deaths from treatment-related events; 9p24.1 alterations were near-universal.","asOf":"2026-09-17","links":[{"label":"J Clin Oncol 2019","url":"https://doi.org/10.1200/JCO.19.01389"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/31609651/"}],"tags":[],"related":[],"cancers":["primary-mediastinal-b-cell-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["keynote-170"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["jco"],"dependsOn":[],"notes":[],"journal":"Journal of Clinical Oncology","year":2019,"doi":"10.1200/JCO.19.01389","pmid":"31609651","authors":"Armand P, Rodig S, Melnichenko V, et al.","paperType":"observational","findings":["Objective response 45 percent; complete response 13 percent.","Median duration of response not reached at 12.5 months."],"whatItMeans":"Pembrolizumab is approved for relapsed primary mediastinal B-cell lymphoma and is the usual bridge to CAR-T or transplant in chemotherapy-refractory patients.","caveats":["Single-arm; small numbers.","Most responders eventually need consolidative therapy."],"changedPractice":true,"participants":53},"route":"/key-papers/paper-keynote-170-pembrolizumab-pmbcl-armand-jco-2019/","neighbours":{"cancer":[{"id":"primary-mediastinal-b-cell-lymphoma","kind":"cancer","name":"Primary mediastinal (thymic) large B-cell lymphoma","route":"/cancers/primary-mediastinal-b-cell-lymphoma/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}],"trial":[{"id":"keynote-170","kind":"trial","name":"KEYNOTE-170","route":"/trials/keynote-170/"}],"journal":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/"}]}}